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Abstract
Human heteromeric amino acid transporters (HATs) are membrane protein complexes that facilitate the transport of specific
amino acids across cell membranes. Loss of function or overexpression of these transporters is implicated in several human
diseases such as renal aminoacidurias and cancer. HATs are composed of two subunits, a heavy and a light subunit, that are
covalently connected by a disulphide bridge. Light subunits catalyse amino acid transport and consist of twelve
transmembrane a-helix domains. Heavy subunits are type II membrane N-glycoproteins with a large extracellular domain
and are involved in the trafficking of the complex to the plasma membrane. Structural information on HATs is scarce
because of the difficulty in heterologous overexpression. Recently, we had a major breakthrough with the overexpression of
a recombinant HAT, 4F2hc-LAT2, in the methylotrophic yeast Pichia pastoris. Microgram amounts of purified protein made
possible the reconstruction of the first 3D map of a human HAT by negative-stain transmission electron microscopy. Here
we report the important stabilization of purified human 4F2hc-LAT2 using a combination of two detergents, i.e., n-dodecyl-
b-D-maltopyranoside and lauryl maltose neopentyl glycol, and cholesteryl hemisuccinate. The superior quality and stability
of purified 4F2hc-LAT2 allowed the measurement of substrate binding by scintillation proximity assay. In addition, an
improved 3D map of this HAT could be obtained. The detergent-induced stabilization of the purified human 4F2hc-LAT2
complex presented here paves the way towards its crystallization and structure determination at high-resolution, and thus
the elucidation of the working mechanism of this important protein complex at the molecular level.
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Introduction
Human heteromeric amino acid transporters (HATs) are
antiporters composed of two subunits, a heavy (SLC3 family)
and a light subunit (SLC7 family) covalently linked by two
conserved cysteine residues [1–3]. Light subunit members are also
called L-type amino acid transporters (LATs) and belong to the
large amino acids, polyamines and organocations (APC) trans-
porter superfamily [4]. The light subunit constitutes the transport
system for large and neutral amino acids, whereas the heavy
subunit is required for the functional expression of the HAT in
plasma membranes [5–7]. Exchange of amino acids by HATs
across membranes is driven in a Na+-independent manner with a
1:1 stoichiometry [8,9]. In humans, two heavy subunits have been
identified, i.e., rBAT and 4F2hc [1]. The latter is involved in the
formation of heterodimeric complexes with six different light
subunits, i.e., LAT1, LAT2, y+LAT1, y+LAT2, asc1 and xCT [3].
Due to the widespread expression of these transport systems in
organs and tissues, HATs are determining factors for a variety of
human diseases, e.g., aminoacidurias (cystinuria and lysinuric
protein intolerance) [7,10,11], tumor cell growth [12,13], Kaposi’s
sarcoma-associated herpesvirus infection [14,15] and cocaine
relapse [16].
Despite the relevance of HATs in human physiology, detailed
structural information has only been published for the extracel-
lular domain of human 4F2hc [17]. The SLC3 family member
4F2hc is a type II membrane N-glycoprotein. 4F2hc is composed
of a single transmembrane (TM) a-helix, an intracellular N-







































terminus and a large extracellular C-terminus [1]. X-ray
crystallography revealed that the structure of the 4F2hc-ectodo-
main (ED) is similar to bacterial glucosidases with the typical triose
phosphate isomerase (TIM) barrel (ba)8 fold and eight additional
antiparallel b-strands [17]. In contrast to the bacterial homologs,
human 4F2hc is missing the catalytic key residues for glucosidase
activity [17]. On the structure of LATs, cysteine-scanning
mutagenesis studies of xCT identified a twelve TM a-helix
topology with intracellular N- and C-termini [18]. Recently, with
the crystal structures of AdiC (L-arginine/agmatine antiporter)
[19–22], ApcT (broad-specificity amino acid transporter) [23] and
GadC (glutamate/GABA antiporter) [24], atomic models of
prokaryotic APC transporters have become available. These
models provide insights into the architecture and molecular
transport mechanisms of APC superfamily members. LATs are
likely to share a common architecture with their distantly related
(#20% amino acid sequence identity) prokaryotic APC homologs,
but to date little information is available on the structure of HATs.
In a recent publication on the expression screening of human
HATs in the methylotrophic yeast Pichia pastoris (P. pastoris), we
identified 4F2hc-LAT2 as a promising candidate for functional
and structural studies of HATs [25]. Furthermore, a first glimpse
on the supramolecular organization of HATs could be obtained
recently for 4F2hc-LAT2 by transmission electron microscopy
(TEM), single particle analysis, cysteine scanning mutagenesis and
disulphide mapping [26]. Using these experimental data, in silico
docking analyses were performed with the 4F2hc-ED structure
and a homology model of LAT2 to predict the contact sites at the
heterodimer interface. Interactions were found between 4F2hc
and the external loop regions of LAT2 indicating that the heavy
subunit acts as a scaffold protein for the stability of the transporter
complex [26]. Stabilization of LAT2 by the 4F2hc-ED was further
corroborated by biochemical experiments. In these two studies
[25,26], His-tagged 4F2hc and StrepII-tagged LAT2 were
overexpressed in P. pastoris and the heterodimer purified from
n-dodecyl-b-D-maltoside (DDM) solubilized membranes. Howev-
er, purification in DDM resulted not only in 4F2hc-LAT2
heterodimers, but also in 4F2hc and LAT2 monomers (from
disrupted heterodimers) and aggregates [25,26]. Size exclusion
chromatography (SEC) profiles of DDM-purified 4F2hc-LAT2
indicated, in addition to the heterodimer peak, heterogeneous
protein populations characterized by a prominent aggregates/
oligomers peak [25]. Substrate binding to purified 4F2hc-LAT2
could not be determined due to the relatively low stability of the
HAT in DDM [26]. Nevertheless, transport activity of the
recombinant human 4F2hc-LAT2 complex was demonstrated by
two different methods, i.e., uptake experiments using Pichia cells
and proteoliposomes reconstituted from isolated, DDM-solubilized
membranes.
Results and Discussion
We significantly improved the stability of detergent-solubilized
4F2hc-LAT2 for ligand-binding experiments and structural
characterization by scintillation proximity assay (SPA) and
TEM/single particle analysis, respectively. The stabilization of
4F2hc-LAT2 was successfully achieved by membrane solubilisa-
tion and protein purification using the two detergents DDM and
lauryl maltose neopentyl glycol (LMNG), and cholesteryl hemi-
succinate (CHS) simultaneously. CHS [27,28] and LMNG [29]
were shown to be beneficial for stability and retaining the function
of purified mammalian membrane proteins (see indicated refer-
ences for details on possible stabilizing mechanisms of CHS and
LMNG). Inspired by these reports, we modified our original
purification protocol [25] and included LMNG and CHS in
addition to DDM.
We purified 4F2hc-LAT2 by sequential cobalt and Strep-Tactin
affinity chromatographies [25] in the presence of DDM, LMNG
and CHS. The integrity, homogeneity and stability of purified
4F2hc-LAT2 heterodimers was analysed by SDS-PAGE, Western
blot analysis and SEC (Fig. 1). SDS-PAGE showed a single protein
band with a molecular mass of ,125 kDa (Fig. 1A; lane C)
corresponding to the purified heterodimer. Importantly, no 4F2hc
and LAT2 monomers, i.e., disrupted heterodimers, or aggregates/
oligomers were detected by Western blotting using anti-4F2hc and
anti-StrepTagII antibodies in stark contrast to purification with
DDM (see Fig. 4A in Ref. [25] and Fig. S1 for comparison). The
presence of LMNG and CHS in addition to DDM even prevented
disruption of 4F2hc-LAT2 heterodimers six days after purification
(Fig. S1). Only some unspecific formation of dimers and higher
oligomers of heterodimers was observed after such periods of time
(Fig. S1A, lower). In contrast, Western blot analysis of DDM-
purified 4F2hc-LAT2 detected significant amounts of 4F2hc and
LAT2 monomers from disrupted heterodimers and high amounts
of aggregates after the same timespan (Fig. S1B, lower). SEC
profiles of 4F2hc-LAT2 purified with DDM/LMNG/CHS
indicated a single almost symmetric peak at a retention volume
of 13.7 ml (Fig. 1B). By comparing retention volumes of purified
4F2hc-LAT2 and soluble molecular weight markers, the molecular
mass of the complex was estimated to be ,406 kDa indicating a
significant amount of bound DDM, LMNG and CHS. Similar to
the purified protein (Fig. 1A), SDS-PAGE and Western blot
analysis of the SEC peak fraction demonstrated full integrity of the
4F2hc-LAT2 heterodimer (Fig. 1C). In summary, purification of
4F2hc-LAT2 in DDM, LMNG and CHS significantly increased
the stability of the complex paving the way for new functional and
structural studies. First, we performed substrate binding to purified
heterodimer using the SPA as previously reported for transport
proteins [30,31]. Fig. 1D (bar 1) shows clear binding of the
substrate [3H]L-leucine to purified 4F2hc-LAT2 by SPA. As
expected, the SPA signal was lost by the addition of 4 mM L-
leucine (Fig. 1D, bar 2) indicating competitive binding of
unlabelled substrate to the heterodimer. The SPA signal was also
lost by the addition of 100 mM imidazole (Fig. 1D, bar 3), which
displaced the 4F2hc-LAT2 from the SPA beads. Second, the
integrity, homogeneity, stability and ability to bind substate of
DDM/LMNG/CHS-purified 4F2hc-LAT2, as determined bio-
chemically, prompted us to perform TEM and single particle
analysis. Fig. 2A shows a representative overview electron
micrograph of negatively-stained 4F2hc-LAT2 complexes. In
contrast to 4F2hc-LAT2 purified only in DDM [26], small protein
aggregates, and 4F2hc or LAT2 monomers from disrupted
heterodimers were rarely found supporting the high integrity,
homogeneity and stability of the complex when purified in DDM/
LMNG/CHS. As for DDM-purified 4F2hc-LAT2 [26], particles
had a distinct shape composed of two globular domains of different
sizes (Fig. 2B). This characteristic feature is even more prominent
in calculated class averages (Fig. S2A) compared to the raw
images. In Rosell et al. we assigned the large and small domains of
DDM-purified heterodimer particles to LAT2 and 4F2hc,
respectively [26]. To further support this assignment experimen-
tally, we performed labelling of the N-terminally located His-tag of
4F2hc using 5 nm Ni-NTA-Nanogold probes. The N-terminus of
4F2hc is located on the cytoplasmic side followed by a single TM
a-helix and the large C-terminal ED, which is located on the
extracellular side. On electron micrographs, the Nanogold probe
was identified at the large domain of 4F2hc-LAT2 heterodimers
and opposite to the small domain (Fig. 2C) supporting our
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previous assignment [26]. We calculated a 3D reconstruction of
DDM/LMNG/CHS-purified 4F2hc-LAT2 from 27’921 nega-
tively-stained complexes (Fig. S2B). The resolution of the obtained
3D map was estimated to 20 A˚ (Fig. S2C). This resolution should
be considered with caution because the 3D reconstruction was
obtained from negatively-stained samples. The distribution of the
particle orientations after the last refinement cycle is shown in Fig.
S2D and indicates a homogenous angular distribution of single
particle projections.
In congruence with the class averages, the 3D model of 4F2hc-
LAT2 exhibits a particular shape consisting of two differently sized
densities (Fig. 3A; for additional views see Fig. S2B). The overall
architecture of the 3D model calculated from DDM/LMNG/
CHS-stabilized 4F2hc-LAT2 is similar to the 3D reconstruction
we previously published [26]. Both models feature a smaller
density on top of a larger one, with the former being clearly tilted
(Fig. 3A, black dotted lines). As a consequence of the tilt, the 3D
map possesses a cavity (Fig. 3A, arrowheads) and a seal (Fig. 3A,
white dotted curve) in the interface region between the smaller and
larger density. We fitted the X-ray structure of 4F2hc-ED [17] into
the smaller density of our 3D model. This resulted in a similar
orientation of the ED structure as seen in our previous 3D map
calculated from 4F2hc-LAT2 purified in DDM (Fig. 3B and 3C)
[26]. The orientation of the ED reveals the approximate
localization of the N-terminal TM a-helix of the heavy-chain
4F2hc (Fig. 3B and 3C, indicated by asterisks). The previous 3D
reconstruction of 4F2hc-LAT2 purified in DDM was calculated
from 15,210 single particle projections. In contrast, the 4F2hc-
LAT2 3D map presented here was calculated from 27’921
negatively-stained complexes, thus containing almost twice the
number of projections. More, importantly, the high protein quality
of isolated 4F2hc-LAT2 when purifying with the DDM, LMNG
and CHS combination allowed us to collect a significantly higher
number of projections of intact complexes. We compared the 3D
Figure 1. SDS-PAGE, Western blot analysis, SEC and SPA of 4F2hc-LAT2 purified in DDM, LMNG and CHS. (A) Coomassie Blue-stained
10% SDS/polyacrylamide gel (lane C) of 4F2hc-LAT2 after the two affinity chromatography steps. The complex runs as a prominent band at
,125 kDa. Western blot analysis using anti-4F2hc (lane a4F2ED) and anti-StrepTagII (lane aSTag) antibodies indicated the presence of intact
heterodimers only, i.e., no 4F2hc or LAT2 from disrupted complexes. (B) SEC of purified 4F2hc-LAT2 indicated a prominent almost symmetrical elution
peak at 13.7 ml. (C) Silver-stained 10% SDS/polyacrylamide gel of purified 4F2hc-LAT2 after gel filtration (lane ST; from peak fraction). Again, one
single band is visible corresponding to the heterodimer. Integrity of the complex was further supported by Western blotting using anti-4F2hc (lane
a4F2ED) and anti-StrepTagII (lane aSTag) antibodies. (D) Radioligand-binding assay by SPA using purified 4F2hc-LAT2 and [
3H]L-leucine. Bar 1: Binding
of the radiolabelled substrate L-leucine to 4F2hc-LAT2, which is bound to scintillation beads, induces SPA signal. As expected, SPA signal was
abolished by addition of 4 mM cold L-leucine (bar 2; competitive inhibition) or 100 mM imidazole (bar 3; detachment of the protein from the SPA
beads). Bars represent mean 6 SEM from triplicates. One representative of three similar independent experiments is shown.
doi:10.1371/journal.pone.0109882.g001
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maps of 4F2hc-LAT2 calculated from protein purified in DDM
[26] and DDM/LMNG/CHS (Fig. S3). While the densities of the
EDs were similar, differences were found in the densities
corresponding to LAT2. In the ellipsoid shaped LAT2 densities,
the short axes differed by 14 A˚ (85 A˚ minus 71 A˚; Fig. S3A) while
the long axes were identical (i.e., 99 A˚; Fig. S3B). Because of the
same long axes, we attribute the obtained shorter axis and density
in the 3D map previously calculated from complexes purified in
DDM [26] to anisotropy in the data set. The 3D reconstruction of
4F2hc-LAT2 presented here was calculated from a significantly
larger data set, thus guaranteeing a superior uniform angular
coverage (i.e., azimuthal angles) of projections (Fig. S2D) and map
quality.
Purification of human membrane proteins for functional and
structural studies remains a challenge nowadays. Even more
challenging is the purification of covalently bound human
membrane protein complexes such as heterodimers where the
connecting disulphide bridge is prone to breakage. Here we
significantly stabilized purified human 4F2hc-LAT2 using a
combination of two detergents, i.e., DDM and LMNG, and
CHS. This made possible the application of the SPA radioligand-
binding assay and the reconstruction of a solid 3D map. The
stabilization of the human 4F2hc-LAT2 complex paves the way
towards its crystallization for structure determination by crystal-
lographic methods, and the elucidation of the molecular working
mechanism of this important protein complex.
Materials and Methods
Overexpression, purification and SEC of 4F2hc-LAT2
Pichia cells overexpressing human 4F2hc-LAT2 were grown in
batch culture or bioreactor as described previously [25,32].
Protein purification was performed similar to Costa et al. [25]
using DDM (Anatrace, USA), LMNG (Anatrace, USA) and CHS
(Sigma-Aldrich), and considering a 1:5 (w/w) ratio between CHS
and total detergent. Briefly, P. pastoris membranes containing
overexpressed 4F2hc-LAT2 were solubilized for 1 h at 4uC under
gentle agitation in 1.5% DDM, 0.1% LMNG and 0.32% CHS in
Buffer P (20 mM Tris–HCl pH 8, 300 mM NaCl and 10%
glycerol). During detergent solubilisation the protein concentration
was 3 mg/ml. After ultracentrifugation (100,000g at 4uC for 1 h),
4F2hc-LAT2 was purified from the supernatant by two sequential
affinity chromatography steps, i.e., cobalt (TALON, Clontech, BD
Biosciences, Germany) and Strep-Tactin (Superflow, high capacity
resin; IBA, Germany) affinity chromatographies. 4F2hc-LAT2 was
bound to a TALON column equilibrated with Buffer P containing
5 mM imidazole, 0.2% DDM, 0.013% LMNG and 0.0426%
CHS. For washing and elution, the same buffer was used
containing 20 mM and 200 mM imidazole, respectively. The
elution was then bound to Strep-Tactin resin and washed in Buffer
P containing 0.1% DDM, 0.0065% LMNG and 0.0213% CHS.
4F2hc-LAT2 was finally eluted with the same buffer supplemented
with 8 mM desthiobiotin (IBA, Germany).
SEC of purified 4F2hc-LAT2 was performed with a Superose 6
10/300 GL column (GE Healthcare) using 20 mM Tris-HCl
pH 8, 150 mM NaCl, 10% glycerol, 0.1% DDM, 0.0065%
LMNG, 0.0213% CHS as elution buffer. The SEC column was
calibrated using the marker proteins: Conalbumin (CA, 75 kDa),
Aldolase (A, 158 kDa), Ferritin (F, 440 kDa) and Thyroglobulin
(TG, 669 kDa), and the molecular weight (Mw) of the complex
was determined similar to Ilgu¨ et al. [33].
SPA of 4F2hc-LAT2
SPA was conducted with purified 4F2hc-LAT2 as described
previously [30] using the following experimental conditions:
4.2 mg of protein, 0.5 mCi [3H]L-leucine (specific activity:
120 Ci/mmol, Perkin Elmer), 300 mg PVT-copper beads (Perkin
Elmer) per 96-well plate (white OptiPlates, Perkin Elmer) well. For
the competition (Fig. 1D, bar 2) and background control (Fig. 1D,
bar 3) experiments, 4 mM L-leucine and 100 mM imidazole were
also present in the mixtures, respectively. The total assay volume
was always 100 ml.
Negative-stain TEM, 3D reconstruction and on-grid
Nanogold labelling
Purified human 4F2hc-LAT2 at ,30 mg/ml protein concen-
tration was adsorbed for,10 s to parlodion carbon-coated copper
grids which were rendered hydrophilic by glow discharge at low
pressure in air. Grids were washed with three drops of double-
distilled water and stained with two drops of 0.75% uranyl formate
(BDH Chemicals, USA). Electron micrographs were recorded
with a Philips CM12 transmission electron microscope operated at
80 kV and equipped with a Morada CCD camera (Soft Imaging
System, Olympus). For image processing and 3D reconstruction,
the software package EMAN2 [34] was used. Initially, 28,993
single particles of 4F2hc-LAT2 were picked with a box size of 128
pixels using the e2boxer program. Electron micrographs were
corrected for the contrast transfer function of the microscope using
the e2ctf program. Reference-free classification and averaging was
done with the e2refine2d program, which yielded about 200 class
averages. From these class averages the e2initialmodel algorithm
built a starting 3D model. The preliminary model was refined
against a final set of 27,921 projections by running the iterative
refinement procedure e2refine. During the refinement process the
angular spacing was decreased from 15u to 2.5u. The resolution of
the final 3D reconstruction was estimated by calculating the
Figure 2. TEM and Nanogold labelling of purified human
4F2hc-LAT2 heterodimers. (A) Electron micrograph of purified
negatively-stained 4F2hc-LAT2 heterodimers. Galleries of unlabelled
(B) and 5 nm Ni-NTA-Nanogold labelled (C) 4F2hc-LAT2 heterodimers.
Bilobed particles with two different sized domains are clearly visible.
The 5 nm Ni-NTA Nanogold spheres are localized to the larger domains
of the heterodimer. The scale bar in (A) represents 50 nm. The frame
size of the boxes in (B) and (C) represent 28 nm.
doi:10.1371/journal.pone.0109882.g002
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Fourier shell correlation (FSC) with the e2eotest program of
EMAN2 and using the 0.5 criterion as a resolution indicator
(conventional FSC calculation, not gold standard). The density
threshold for volume rendering of the 4F2hc-LAT2 map was
determined by fitting the surface representation of the 4F2hc
ectodomain (4F2hc-ED; PDB: 2DH2) crystal structure into the
small density of the 3D reconstruction and adjusting the threshold.
Visualization of the 3D model and fitting of the 4F2hc-ED crystal
structure was done in UCSF Chimera [35].
For Nanogold labelling, purified 4F2hc-LAT2 was adsorbed to
electron microscopy grids as described above. Grids were washed
with three drops of double-distilled water and blotted. Then
immediately, 10 ml of 5 nm Ni-NTA Nanogold solution (Nanop-
robes Inc., USA) diluted 1:5 in 60 mM Tris-HCl pH 8, 450 mM
NaCl, 2.5 mM imidazole) were added. Grids were incubated for
30 min at room temperature in a humidity chamber (Petri dish
with wet paper towel inside). After incubation, grids were blotted
to remove the Nanogold solution, washed with one drop of
double-distilled water and finally negatively-stained with 0.75%
uranyl formate.
Supporting Information
Figure S1 Stability of purified human 4F2hc-LAT2. SDS-
PAGE and Western blot analyses of 4F2hc-LAT2 purified in
DDM, LMNG and CHS (A), and DDM only (B) after purification
(day 1; upper) and 6 days later (lower). Purified protein was always
kept on ice or 4uC. Western blot analysis was performed using
anti-4F2hc (lanes a4F2ED) and anti-StrepTagII (lanes aSTag)
antibodies. 10% SDS/polyacrylamide gels were used. Gels in lanes
C were stained with Coomassie Blue. In (A) no disruption of the
complex was observed (upper). Only some higher aggregates were
observed 6 days after purification (lower). In stark contrast, 4F2hc
and LAT2 monomers from disrupted heterodimers as well as some
higher aggregates were found in 4F2hc-LAT2 purified in DDM
after purification (B) (upper). Incubation at 4uC for additional 6
days dramatically increased aggregation of the complex. In all
lanes C, 5 mg protein were loaded with the exception of lane C in
lower, panel (B). Here 20 mg were loaded in order to visualize
bands not corresponding to higher aggregates (which were most
abundant).
(TIF)
Figure S2 Single particle analysis and 3D reconstruc-
tion of human 4F2hc-LAT2. (A) Representative class averages
of 4F2hc-LAT2 purified in DDM, LMNG and CHS. The
reference-free class averages of the heterodimer were generated
from 27’921 single projections. The frame size of the class averages
is 39.6 nm. (B) Overview of the 3D reconstruction of 4F2hc-
LAT2. The 3D model is rotated in increments of 45u around the
x- (lower) or y-axis (upper). The scale bar represents 5 nm. (C)
Resolution of the 4F2hc-LAT2 3D map. According to the 0.5
criterion the Fourier Shell Correlation (FSC) function indicates a
resolution of 20 A˚. (D) The Euler angle distribution of single
particle projections demonstrates a homogeneous sampling.
(TIF)
Figure S3 Comparison of human 4F2hc-LAT2 3D recon-
structions. Front (A) and side (B) views of 3D maps of 4F2hc-
Figure 3. 3D reconstruction of human 4F2hc-LAT2 purified in DDM, LMNG and CHS. (A) Side views of the 3D map calculated from 27’921
projections of negatively-stained heterodimer particles (initially 28’993 picked). 4F2hc-LAT2 has a bilobed structure and consists of a smaller tilted
density located on top of a larger density (tilt indicated by black dotted lines). As a consequence of the tilt, the 3D map features a distinct cavity
(arrowheads) and on the opposite side a seal (marked by a white, dotted curve). Based on the Fourier shell correlation curve (0.5 criterion) the
resolution is 20 A˚ (Fig. S2C). (B) and (C) Different views of the 4F2hc-LAT2 3D map with the fitted crystal structure of the 4F2hc-ED (PDB ID: 2DH2).
Asterisks in (B) and (C) indicate the location of the N-terminus in the 4F2hc-ED crystal structure. The 4F2hc-ED structure is represented as cartoon (a-
helices and b-strands in red and blue, respectively) and surface (CPK colours) models. The scale bar represents 50 A˚.
doi:10.1371/journal.pone.0109882.g003
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LAT2 purified with DDM/LMNG/CHS (in grey) and with DDM
only (in yellow). In (A) and (B), the X-ray crystal structure of
4F2hc-ED is shown as surface representation (PDB: 2DH2; CPK
colours). In (A) the measured widths of LAT2 are different, i.e.,
85 A˚ versus 71 A˚, while in (B) identical, i.e., 99 A˚.
(TIF)
Author Contributions
Conceived and designed the experiments: MM MC DF. Performed the
experiments: MM MC MS JMJ BB HI. Analyzed the data: MM MC DH
DF. Contributed reagents/materials/analysis tools: BB AR KK MP.
Wrote the paper: MM MC DF.
References
1. Fotiadis D, Kanai Y, Palacin M (2013) The SLC3 and SLC7 families of amino
acid transporters. Mol Aspects Med 34: 139–158.
2. Palacin M, Kanai Y (2004) The ancillary proteins of HATs: SLC3 family of
amino acid transporters. Pflugers Arch 447: 490–494.
3. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, et al. (2004) CATs and
HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447: 532–542.
4. Verrey F, Jack DL, Paulsen IT, Saier MH, Jr., Pfeiffer R (1999) New
glycoprotein-associated amino acid transporters. J Membr Biol 172: 181–192.
5. Reig N, Chillaron J, Bartoccioni P, Fernandez E, Bendahan A, et al. (2002) The
light subunit of system b(o,+) is fully functional in the absence of the heavy
subunit. EMBO J 21: 4906–4914.
6. Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, et al. (1998)
Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
permease family. Nature 395: 288–291.
7. Torrents D, Estevez R, Pineda M, Fernandez E, Lloberas J, et al. (1998)
Identification and characterization of a membrane protein (y+L amino acid
transporter-1) that associates with 4F2hc to encode the amino acid transport
activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem
273: 32437–32445.
8. Chillaron J, Estevez R, Mora C, Wagner CA, Suessbrich H, et al. (1996)
Obligatory amino acid exchange via systems bo,+-like and y+L-like. A tertiary
active transport mechanism for renal reabsorption of cystine and dibasic amino
acids. J Biol Chem 271: 17761–17770.
9. Busch AE, Herzer T, Waldegger S, Schmidt F, Palacin M, et al. (1994) Opposite
directed currents induced by the transport of dibasic and neutral amino acids in
Xenopus oocytes expressing the protein rBAT. J Biol Chem 269: 25581–25586.
10. Feliubadalo L, Font M, Purroy J, Rousaud F, Estivill X, et al. (1999) Non-type I
cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of
rBAT. Nat Genet 23: 52–57.
11. Calonge MJ, Gasparini P, Chillaron J, Chillon M, Gallucci M, et al. (1994)
Cystinuria caused by mutations in rBAT, a gene involved in the transport of
cystine. Nat Genet 6: 420–425.
12. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, et al. (2009)
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell
136: 521–534.
13. Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in
cancer: partners in crime? Semin Cancer Biol 15: 254–266.
14. Veettil MV, Sadagopan S, Sharma-Walia N, Wang FZ, Raghu H, et al. (2008)
Kaposi’s sarcoma-associated herpesvirus forms a multimolecular complex of
integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during
infection of human dermal microvascular endothelial cells, and CD98-xCT is
essential for the postentry stage of infection. J Virol 82: 12126–12144.
15. Kaleeba JA, Berger EA (2006) Kaposi’s sarcoma-associated herpesvirus fusion-
entry receptor: cystine transporter xCT. Science 311: 1921–1924.
16. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, et al. (2003)
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat
Neurosci 6: 743–749.
17. Fort J, de la Ballina LR, Burghardt HE, Ferrer-Costa C, Turnay J, et al. (2007)
The structure of human 4F2hc ectodomain provides a model for homodimer-
ization and electrostatic interaction with plasma membrane. J Biol Chem 282:
31444–31452.
18. Gasol E, Jimenez-Vidal M, Chillaron J, Zorzano A, Palacin M (2004)
Membrane topology of system xc
2 light subunit reveals a re-entrant loop with
substrate-restricted accessibility. J Biol Chem 279: 31228–31236.
19. Kowalczyk L, Ratera M, Paladino A, Bartoccioni P, Errasti-Murugarren E, et al.
(2011) Molecular basis of substrate-induced permeation by an amino acid
antiporter. Proc Natl Acad Sci USA 108: 3935–3940.
20. Gao X, Zhou L, Jiao X, Lu F, Yan C, et al. (2010) Mechanism of substrate
recognition and transport by an amino acid antiporter. Nature 463: 828–832.
21. Fang Y, Jayaram H, Shane T, Kolmakova-Partensky L, Wu F, et al. (2009)
Structure of a prokaryotic virtual proton pump at 3.2 A˚ resolution. Nature 460:
1040–1043.
22. Gao X, Lu F, Zhou L, Dang S, Sun L, et al. (2009) Structure and mechanism of
an amino acid antiporter. Science 324: 1565–1568.
23. Shaffer PL, Goehring A, Shankaranarayanan A, Gouaux E (2009) Structure and
mechanism of a Na+-independent amino acid transporter. Science 325: 1010–
1014.
24. Ma D, Lu P, Yan C, Fan C, Yin P, et al. (2012) Structure and mechanism of a
glutamate-GABA antiporter. Nature 483: 632–636.
25. Costa M, Rosell A, Alvarez-Marimon E, Zorzano A, Fotiadis D, et al. (2013)
Expression of human heteromeric amino acid transporters in the yeast Pichia
pastoris. Protein Expr Purif 87: 35–40.
26. Rosell A, Meury M, Alvarez-Marimon E, Costa M, Perez-Cano L, et al. (2014)
Structural bases for the interaction and stabilization of the human amino acid
transporter LAT2 with its ancillary protein 4F2hc. Proc Natl Acad Sci USA 111:
2966–2971.
27. Drew D, Newstead S, Sonoda Y, Kim H, von Heijne G, et al. (2008) GFP-based
optimization scheme for the overexpression and purification of eukaryotic
membrane proteins in Saccharomyces cerevisiae. Nat Protoc 3: 784–798.
28. O’Malley MA, Helgeson ME, Wagner NJ, Robinson AS (2011) The
morphology and composition of cholesterol-rich micellar nanostructures
determine transmembrane protein (GPCR) activity. Biophys J 100: L11–L13.
29. Chae PS, Rasmussen SG, Rana RR, Gotfryd K, Chandra R, et al. (2010)
Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization
and crystallization of membrane proteins. Nat Methods 7: 1003–1008.
30. Harder D, Fotiadis D (2012) Measuring substrate binding and affinity of purified
membrane transport proteins using the scintillation proximity assay. Nature
Protoc 7: 1569–1578.
31. Quick M, Javitch JA (2007) Monitoring the function of membrane transport
proteins in detergent-solubilized form. Proc Natl Acad Sci USA 104: 3603–3608.
32. Hyka P, Zullig T, Ruth C, Looser V, Meier C, et al. (2010) Combined use of
fluorescent dyes and flow cytometry to quantify the physiological state of Pichia
pastoris during the production of heterologous proteins in high-cell-density fed-
batch cultures. Appl Environ Microbiol 76: 4486–4496.
33. Ilgu¨ H, Jeckelmann JM, Gachet MS, Boggavarapu R, Ucurum Z, et al. (2014)
Variation of the detergent-binding capacity and phospholipid content of
membrane proteins when purified in different detergents. Biophys J 106:
1660–1670.
34. Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, et al. (2007) EMAN2: an
extensible image processing suite for electron microscopy. J Struct Biol 157: 38–
46.
35. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al.
(2004) UCSF Chimera—a visualization system for exploratory research and
analysis. J Comput Chem 25: 1605–1612.
Stabilization and 3D Map of Human 4F2hc-LAT2
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109882
